Tuberculosis-resistant cows developed for the first time using CRISPR technology
CRISPR/Cas9 gene-editing technology has been used for the first time to successfully produce live cows with increased resistance to bovine tuberculosis, reports new research published in the open access journal Genome Biology.
The researchers, from the College of Veterinary Medicine, Northwest A&F University in Shaanxi, China, used a modified version of the CRISPR gene-editing technology to insert a new gene into the cow genome with no detected off target effects on the animals genetics (a common problem when creating transgenic animals using CRISPR).
Dr Yong Zhang, lead author of the research, said: "We used a novel version of the CRISPR system called CRISPR/Cas9n to successfully insert a tuberculosis resistance gene, called NRAMP1, into the cow genome. We were then able to successfully develop live cows carrying increased resistance to tuberculosis. Importantly, our method produced no off target effects on the cow genetics meaning that the CRISPR technology we employed may be better suited to producing transgenic livestock with purposefully manipulated genetics."
CRISPR technology has become widely used in the laboratory in recent years as it is an accurate and relatively easy way to modify the genetic code. However, sometimes unintentional changes to the genetic code occur as an off target effect, so finding ways to reduce these is a priority for genomics research.
Dr Zhang explained: "When you want to insert a new gene into a mammalian genome, the difficulty can be finding the best place in the genome to insert the gene. You have to hunt through the genome, looking for a region that you think will have the least impact on other genes that are in close proximity. We employed a meticulous and methodological approach to identify the best suited region for gene insertion, which we show has no detectable off target effects on the bovine genome".
The researchers inserted the NRAMP1 gene into the genome of bovine foetal fibroblasts — a cell derived from female dairy cows — using the CRISPR/Cas9n technology. These cells were then used as donor cells in a process called somatic cell nuclear transfer, where the nucleus of a donor cell carrying the new gene is inserted into an egg cell, known as an ovum, from a female cow. Ova were nurtured in the lab into embryos before being transferred into mother cows for a normal pregnancy cycle. The experiments were also conducted using the standard CRISPR/Cas9 technology as a comparison.
total of 11 calves with new genes inserted using CRISPR were able to be assessed for resistance to tuberculosis and any off target genetic effects. Genetic analysis of the calves revealed that NRAMP1 had successfully integrated into the genetic code at the targeted region in all of the calves. None of the calves that had the gene inserted using the new CRISPR/Cas9n technology had any detectable off target effects whereas all of the calves with the gene inserted with previously used techniques for CRISPR/Cas9 did.
When the calves were exposed to M. bovis, the bacterium that causes bovine tuberculosis, the researchers found that transgenic animals showed an increased resistance to the bacteria measured by standard markers of infection in a blood sample. They also found that white blood cells taken from the calves were much more resistant to M. bovis exposure in laboratory tests.
Dr Zhang said: "Our study is the first demonstrating that the CRISP/Cas9n system can be used to create transgenic livestock with no detectable off target effects. Our work has led to the discovery of a useful position in the bovine genome that can be targeted with this gene editing technology to successfully insert new genes that benefit agricultural livestock."
T: +44 (0)20 3192 2722
M: +44 (0)75 4079 9187
Notes to editor:
1. Research article:
Title: Single Cas9 nickase induced generation of NRAMP1 knockin cattle with reduced off-target effects
Author: Yong Zhang et al.
Genome Biology February 2017
During embargo period, please contact Matthew Lam for the full article.
After the embargo lifts, the article will be available at the journal website here: http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1144-4
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
2. Genome Biology publishes outstanding research in all areas of biology and biomedicine studied from a genomic and post-genomic perspective.
The current impact factor is 11.313 and the journal is ranked 4th among research journals in the Genetics and Heredity category by Thomson Reuters. Genome Biology is the highest ranked Open Access journal in the category.
3. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Nature, a major new force in scientific, scholarly, professional and educational publishing, created in May 2015 through the combination of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. http://www.biomedcentral.com